Pfizer Inc (PFE) shareholders
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3044% above fair value
$28.83−0.62 (-2.11%)
Close on Nov 12, 2026Market cap $164.32BP/E 41.2Yield 5.97%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
67.2%
3.83B of 5.70B shares
Institutional holders
2,823
155 new, 235 sold out
Net institutional buying
76M
In Q2 2026
Insider trades, 12 months
3 buys · 2 sales
Net bought $2.83M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 434,748,255 | 7.70% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 427,444,872 | 7.51% | 13G (passive) | Mar 31, 2026 |
| State Street Corporation | – | 5.10% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PFE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 529,670,433 | 9.29% | $12.75B | +31,412,883 | 0.19% |
| Vanguard Capital Management LLC | 372,149,852 | 6.53% | $8.96B | +2,719,840 | 0.19% |
| State Street Corp | 307,090,897 | 5.39% | $7.39B | +5,501,032 | 0.22% |
| Geode Capital Management, LLC | 135,275,782 | 2.37% | $3.25B | +1,714,040 | 0.17% |
| Vanguard Portfolio Management LLC | 119,235,030 | 2.09% | $2.87B | +2,500,335 | 0.13% |
| Fisher Asset Management, LLC | 109,067,291 | 1.91% | $2.63B | +4,102,864 | 0.78% |
| Morgan Stanley | 96,345,452 | 1.69% | $2.32B | +3,660,082 | 0.12% |
| Norges Bank | 61,505,586 | 1.08% | $1.48B | New | 0.15% |
| Northern Trust Corp | 59,084,573 | 1.04% | $1.42B | −2,941,979 | 0.17% |
| Bank of New York Mellon Corp | 57,879,546 | 1.02% | $1.39B | +3,999,646 | 0.23% |
| Massachusetts Financial Services Co /Ma/ | 56,551,011 | 0.99% | $1.38B | −360,819 | 0.44% |
| State Farm Mutual Automobile Insurance Co | 54,508,560 | 0.96% | $1.31B | – | 0.90% |
| Goldman Sachs Group Inc | 52,991,850 | 0.93% | $1.28B | +5,886,294 | 0.11% |
| Charles Schwab Investment Management Inc | 52,548,228 | 0.92% | $1.27B | +656,592 | 0.17% |
| Bank Of America Corp /De/ | 43,588,109 | 0.76% | $1.05B | −2,957,370 | 0.07% |
| Legal & General Group Plc | 43,233,122 | 0.76% | $1.04B | −272,441 | 0.22% |
| Dimensional Fund Advisors LP | 38,060,345 | 0.67% | $916.63M | +1,637,546 | 0.17% |
| UBS Asset Management Americas Inc | 36,157,306 | 0.63% | $870.67M | +1,634,374 | 0.16% |
| Amundi | 33,533,616 | 0.59% | $807.49M | −7,291,854 | 0.19% |
| Royal Bank of Canada | 32,814,260 | 0.58% | $790.17M | −1,341,580 | 0.12% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 2,823 | 3.83B | 67.2% | 155 / 1160 | 1213 / 235 | 270M | 194M |
| Q1 2026 | 2,955 | 3.76B | 66.0% | 256 / 1306 | 1087 / 169 | 779M | 222M |
| Q4 2025 | 2,915 | 3.75B | 65.9% | 329 / 1080 | 1268 / 172 | 309M | 207M |
| Q3 2025 | 2,818 | 3.66B | 64.2% | 206 / 1123 | 1221 / 152 | 205M | 299M |
| Q2 2025 | 2,814 | 3.76B | 66.0% | 143 / 1181 | 1232 / 230 | 241M | 228M |
| Q1 2025 | 2,936 | 3.76B | 65.9% | 181 / 1283 | 1203 / 189 | 342M | 319M |
| Q4 2024 | 2,999 | 3.76B | 65.9% | 379 / 937 | 1468 / 246 | 262M | 295M |
| Q3 2024 | 2,916 | 3.80B | 66.7% | 193 / 1241 | 1204 / 124 | 627M | 178M |
| Q2 2024 | 2,879 | 3.79B | 66.4% | 211 / 1187 | 1242 / 173 | 178M | 394M |
| Q1 2024 | 2,880 | 4.01B | 70.4% | 193 / 1226 | 1248 / 218 | 318M | 306M |
| Q4 2023 | 2,940 | 4.01B | 70.3% | 329 / 869 | 1588 / 270 | 333M | 239M |
| Q3 2023 | 2,931 | 3.92B | 68.7% | 127 / 1190 | 1386 / 207 | 168M | 179M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
946 funds held PFE in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PFE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 180,944,898 | 3.17% | $4.36B | 0.19% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 147,700,066 | 2.59% | $3.56B | 0.21% | Jun 30, 2026 |
| iShares Core S&P 500 ETF | 78,364,949 | 1.37% | $1.89B | 0.21% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 72,760,111 | 1.28% | $1.90B | 0.23% | May 31, 2026 |
| Vanguard Value Index Fund | 54,248,096 | 0.95% | $1.31B | 0.51% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 40,264,803 | 0.71% | $969.58M | 2.39% | Jun 30, 2026 |
| Vanguard Institutional Index Fund | 30,941,396 | 0.54% | $745.07M | 0.21% | Jun 30, 2026 |
| iShares Core High Dividend ETF | 25,420,952 | 0.45% | $635.78M | 4.27% | Jul 31, 2026 |
| Vanguard High Dividend Yield Index Fund | 22,923,592 | 0.40% | $573.32M | 0.58% | Jul 31, 2026 |
| iShares Select Dividend ETF | 18,810,080 | 0.33% | $470.44M | 2.00% | Jul 31, 2026 |
| First Trust Morningstar Dividend Leaders Index Fund | 17,883,531 | 0.31% | $430.64M | 5.91% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 17,075,747 | 0.30% | $447.04M | 2.35% | May 31, 2026 |
| MFS Value Fund | 15,033,063 | 0.26% | $393.57M | 0.77% | May 31, 2026 |
| New Perspective Fund | 14,451,200 | 0.25% | $347.98M | 0.20% | Jun 30, 2026 |
| Pacer US Cash Cows 100 ETF | 13,728,675 | 0.24% | $343.35M | 1.84% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Albert Bourla | Chairman & CEO, Director | 435,555 | 0.01% | Nov 3, 2026 |
| Cecile Guegan | Executive Vice President | 149,505 | 0.00% | Aug 28, 2026 |
| Jennifer B. Damico | SVP & Controller | 28,611 | 0.00% | Aug 6, 2026 |
| Dennis P. Hancock | Executive Vice President | 47,037 | 0.00% | Apr 27, 2026 |
| Payal Sahni | Executive Vice President | 97,446 | 0.00% | Mar 5, 2026 |
| David M. Denton | Chief Financial Officer & EVP | 37,919 | 0.00% | Mar 5, 2026 |
| Andrew Baum | Executive Vice President | – | – | Mar 5, 2026 |
| Christoffel Boshoff | President, R&D | 168,921 | 0.00% | Mar 5, 2026 |
| Douglas M. Lankler | Executive Vice President | 284,269 | 0.00% | Mar 5, 2026 |
| Michael McDermott | Executive Vice President | 74,308 | 0.00% | Mar 5, 2026 |
| Aamir Malik | Executive Vice President | 29,548 | 0.00% | Mar 5, 2026 |
| Germay Alexandre de | Executive Vice President | 74,377 | 0.00% | Mar 5, 2026 |
| Lidia Fonseca | Executive Vice President | 46,455 | 0.00% | Mar 5, 2026 |
| Sally Susman | Executive Vice President | 169,775 | 0.00% | Mar 6, 2025 |
| Rady A. Johnson | Executive Vice President | 127,242 | 0.00% | Jan 3, 2025 |
| James Quincey | Director | – | – | Sep 29, 2026 |
| Mortimer J. Buckley | Director | 37,632 | 0.00% | Sep 29, 2026 |
| Joseph Echevarria | Director | – | – | Sep 29, 2026 |
| Shantanu Narayen | Director | – | – | Sep 29, 2026 |
| James C. Smith | Director | 3,542 | 0.00% | Sep 29, 2026 |
| Cyrus Taraporevala | Director | 10,000 | 0.00% | Sep 29, 2026 |
| Ronald E. Blaylock | Director | 71,688 | 0.00% | Aug 5, 2026 |
| Dan R. Littman | Director | – | – | Apr 27, 2026 |
| Susan Desmond-Hellmann | Director | 3,408 | 0.00% | Apr 27, 2026 |
| Johnson Suzanne M. Nora | Director | 10,000 | 0.00% | Apr 27, 2026 |
| Scott Gottlieb | Director | 10,000 | 0.00% | Apr 27, 2026 |
| Susan Hockfield | Director | – | – | Apr 28, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Albert Bourla Chairman & CEO, Director | Aug 12, 2026 | Buy | +38,000 | $26.34 | $1.00M | 429,173 |
| Jennifer B. Damico SVP & Controller | Aug 5, 2026 | Sale | −3,278 | $25.40 | $83.26K | 28,611 |
| Ronald E. Blaylock Director | Aug 5, 2026 | Buy | +39,231 | $25.46 | $998.82K | 66,938 |
| Mortimer J. Buckley Director | Aug 5, 2026 | Buy | +37,632 | $25.52 | $960.37K | 37,632 |
| Jennifer B. Damico SVP & Controller | Jun 9, 2026 | Sale | −2,000 | $25.70 | $51.40K | 31,397 |
| Jennifer B. Damico SVP & Controller | Mar 4, 2026 | Tax withholding | −826 | $26.62 | $21.99K | 32,934 |
| Jennifer B. Damico SVP & Controller | Mar 3, 2026 | Award | +5,408 | – | – | 33,760 |
| Jennifer B. Damico SVP & Controller | Mar 3, 2026 | Award | +16,311 | – | – | 28,352 |
| Jennifer B. Damico SVP & Controller | Feb 27, 2026 | Tax withholding | −655 | $27.65 | $18.11K | 12,041 |
| Michael McDermott Executive Vice President | Feb 26, 2026 | Tax withholding | −3,503 | $27.10 | $94.93K | 74,308 |
| Payal Sahni Executive Vice President | Feb 25, 2026 | Option exercise | +56,888 | $33.82 | $1.92M | 82,816 |
| Payal Sahni Executive Vice President | Feb 25, 2026 | Tax withholding | −54,066 | $26.92 | $1.46M | 27,667 |
| Payal Sahni Executive Vice President | Feb 25, 2026 | Tax withholding | −1,083 | $27.09 | $29.34K | 81,733 |
| Jennifer B. Damico SVP & Controller | Feb 25, 2026 | Tax withholding | −361 | $27.09 | $9.78K | 29,383 |
| Jennifer B. Damico SVP & Controller | Feb 25, 2026 | Tax withholding | −16,687 | $26.92 | $449.21K | 12,696 |
| Jennifer B. Damico SVP & Controller | Feb 25, 2026 | Option exercise | +17,558 | $33.82 | $593.81K | 29,744 |
| Michael McDermott Executive Vice President | Feb 25, 2026 | Option exercise | +37,925 | $33.82 | $1.28M | 114,534 |
| Michael McDermott Executive Vice President | Feb 25, 2026 | Tax withholding | −679 | $27.09 | $18.39K | 113,855 |
| Michael McDermott Executive Vice President | Feb 25, 2026 | Tax withholding | −36,044 | $26.92 | $970.30K | 77,811 |
| Douglas M. Lankler Executive Vice President | Feb 25, 2026 | Option exercise | +122,907 | $33.82 | $4.16M | 282,186 |
| Douglas M. Lankler Executive Vice President | Feb 25, 2026 | Tax withholding | −2,198 | $27.09 | $59.54K | 279,988 |
| Douglas M. Lankler Executive Vice President | Feb 25, 2026 | Tax withholding | −116,811 | $26.92 | $3.14M | 163,177 |
| Christoffel Boshoff President, R&D | Feb 25, 2026 | Award | +13,383 | – | – | 168,212 |
| Christoffel Boshoff President, R&D | Feb 25, 2026 | Tax withholding | −6,833 | $27.09 | $185.11K | 161,379 |
| Albert Bourla Chairman & CEO, Director | Feb 25, 2026 | Tax withholding | −467,241 | $26.92 | $12.58M | 388,671 |
| Albert Bourla Chairman & CEO, Director | Feb 25, 2026 | Option exercise | +491,626 | $33.82 | $16.63M | 864,215 |
| Albert Bourla Chairman & CEO, Director | Feb 25, 2026 | Tax withholding | −8,303 | $27.09 | $224.93K | 855,912 |
| Lidia Fonseca Executive Vice President | Feb 25, 2026 | Tax withholding | −54,066 | $26.92 | $1.46M | 46,455 |
| Lidia Fonseca Executive Vice President | Feb 25, 2026 | Tax withholding | −1,058 | $27.09 | $28.66K | 100,521 |
| Lidia Fonseca Executive Vice President | Feb 25, 2026 | Option exercise | +56,888 | $33.82 | $1.92M | 101,579 |
| Christoffel Boshoff President, R&D | Feb 23, 2026 | Tax withholding | −816 | $27.06 | $22.08K | 154,829 |
| Jennifer B. Damico SVP & Controller | Feb 23, 2026 | Tax withholding | −419 | $27.06 | $11.34K | 12,186 |
| Christoffel Boshoff President, R&D | Jan 30, 2026 | Tax withholding | −12,887 | $26.44 | $340.73K | 155,645 |
| Jennifer B. Damico SVP & Controller | Mar 4, 2025 | Sale | −2,500 | $25.93 | $64.83K | 11,850 |
| Jennifer B. Damico SVP & Controller | Mar 4, 2025 | Award | +5,583 | – | – | 14,350 |
| Jennifer B. Damico SVP & Controller | Feb 27, 2025 | Tax withholding | −749 | $26.10 | $19.55K | 29,761 |
| Payal Sahni Executive Vice President | Feb 27, 2025 | Tax withholding | −468 | $26.10 | $12.21K | 43,774 |
| Payal Sahni Executive Vice President | Feb 27, 2025 | Option exercise | +19,054 | $31.31 | $596.58K | 44,242 |
| Payal Sahni Executive Vice President | Feb 27, 2025 | Tax withholding | −17,846 | $26.06 | $465.07K | 25,928 |
| Douglas M. Lankler Executive Vice President | Feb 27, 2025 | Tax withholding | −3,589 | $26.10 | $93.67K | 306,201 |
| Douglas M. Lankler Executive Vice President | Feb 27, 2025 | Tax withholding | −146,961 | $26.06 | $3.83M | 159,240 |
| Douglas M. Lankler Executive Vice President | Feb 27, 2025 | Option exercise | +156,914 | $31.31 | $4.91M | 309,790 |
| Jennifer B. Damico SVP & Controller | Feb 27, 2025 | Option exercise | +22,416 | $31.31 | $701.84K | 31,063 |
| Jennifer B. Damico SVP & Controller | Feb 27, 2025 | Tax withholding | −20,994 | $26.06 | $547.10K | 9,516 |
| Jennifer B. Damico SVP & Controller | Feb 27, 2025 | Tax withholding | −553 | $26.10 | $14.43K | 30,510 |
| Michael McDermott Executive Vice President | Feb 27, 2025 | Tax withholding | −45,347 | $26.06 | $1.18M | 75,958 |
| Michael McDermott Executive Vice President | Feb 27, 2025 | Tax withholding | −1,108 | $26.10 | $28.92K | 121,305 |
| Michael McDermott Executive Vice President | Feb 27, 2025 | Option exercise | +48,419 | $31.31 | $1.52M | 122,413 |
| Albert Bourla Chairman & CEO, Director | Feb 27, 2025 | Tax withholding | −18,300 | $26.10 | $477.63K | 913,444 |
| Albert Bourla Chairman & CEO, Director | Feb 27, 2025 | Option exercise | +582,823 | $31.31 | $18.25M | 931,744 |
| Albert Bourla Chairman & CEO, Director | Feb 27, 2025 | Tax withholding | −545,855 | $26.06 | $14.22M | 367,589 |
| Sally Susman Executive Vice President | Feb 27, 2025 | Tax withholding | −79,779 | $26.06 | $2.08M | 168,909 |
| Sally Susman Executive Vice President | Feb 27, 2025 | Tax withholding | −2,178 | $26.10 | $56.85K | 248,688 |
| Sally Susman Executive Vice President | Feb 27, 2025 | Option exercise | +85,182 | $31.31 | $2.67M | 250,866 |
| Christoffel Boshoff President, R&D | Feb 27, 2025 | Award | +17,450 | – | – | 172,147 |
| Christoffel Boshoff President, R&D | Feb 27, 2025 | Tax withholding | −8,909 | $26.10 | $232.52K | 163,238 |
| Lidia Fonseca Executive Vice President | Feb 27, 2025 | Option exercise | +72,629 | $31.31 | $2.27M | 111,534 |
| Lidia Fonseca Executive Vice President | Feb 27, 2025 | Tax withholding | −68,022 | $26.06 | $1.77M | 41,829 |
| Lidia Fonseca Executive Vice President | Feb 27, 2025 | Tax withholding | −1,683 | $26.10 | $43.93K | 109,851 |
| Michael McDermott Executive Vice President | Feb 26, 2025 | Tax withholding | −3,220 | $26.42 | $85.07K | 73,994 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.36%
134M shares short
Days to cover
4.6
At 29M shares a day
Change since last report
-2.5%
From 138M shares
Short volume, 20 days
40.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pfizer's stock actually held short. Settlement fails (shares not delivered on time) peaked at 282,511 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mikael Dolsten Former Officer | May 23, 2025 | 59,781 | $1.38M | May 23, 2025 | Restricted Stock Vesting |
| Mikael Dolsten Former Officer | May 5, 2025 | 55,000 | $1.31M | May 5, 2025 | Restricted Stock Vesting |
| Pao William Former Chief Development Officer; EVP | Sep 13, 2023 | 54,379 | $1.85M | Sep 13, 2023 | Restricted Stock Vesting |
See a number that looks wrong?